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Tailoring medical treatment to individual patients requires a strong foundation in research
to provide the data necessary to understand the relationship between the disease, the
patient, and the type of treatment advocated for. Non-therapeutic oncology clinical trials
studying therapeutic resistance require the participation of patients, yet only a small per-
centage enroll. Treating physicians are often relied on to recruit patients, but they have
a number of ethical obligations that might be perceived as barriers to recruiting. Con-
cepts such as voluntariness of consent and conflicts of interest can have an impact on
whether physicians will discuss clinical trials with their patients and how patients perceive
the information. However, these ethical obligations should not be prohibitive to physician
recruitment of patients – precautions can be taken to ensure that patients’ consent to
research participation is fully voluntary and devoid of conflict, such as the use of other
members of the research team than the treating physician to discuss the trial and obtain
consent, and better communication between researchers, clinicians, and patients. These
can ensure that research benefits are maximized for the good of patients and society.
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INTRODUCTION
There is a strong drive to provide personalized care in modern
oncology practice (Schilsky, 2010). Tailoring medical treatment to
individual patients, the centerpiece of the personalized medicine
movement, requires a strong foundation in research to provide the
data necessary to understand the relationship between the disease,
the patient, and the type of treatment advocated for.
In cancer genomics, much of personalized medicine has turned
toward therapeutic resistance: why are some patients resistant to
targeted therapies despite expressing the druggable target? What
are the mechanisms of acquired resistance and how can we cir-
cumscribe these? To answer these questions, traditional models
of clinical trials cannot always be relied upon, as the intention is
not to evaluate efficacy, but to give researchers clues as to how to
improve treatment, either through rationale drug combinations
or new drug designs. Many studies now require archived tumor
tissue as entry criteria to a trial, or make use of banked tissue
obtained through hospital biobanks to gain insight into the mech-
anism of action of the drug. In contrast, other studies ask that
patients consent to a separate tissue procurement procedure for
research purposes.
Especially for research into resistance mechanisms, many stud-
ies fall within this second category and must find participants who
are willing to explicitly consent to biopsy-driven studies. This is
exemplified in two trials led by the Quebec-Clinical Research Orga-
nization in Cancer (Q-CROC) on therapeutic resistance in colon
cancer and breast cancer (clinicaltrial.gov identifier NCT00984048
and NCT01276899), and in many other studies of therapeutic
resistance (Sequist et al., 2011; Doebele et al., 2012; Katayama
et al., 2012; Shi et al., 2012). In these examples, patients consent
to a non-therapeutic biopsy from a metastatic lesion that has pro-
gressed despite therapy. While the risks incurred are not high, they
are more than minimal and without the expectation of clinical
benefit to the patient from participation.
The need for patient participation in oncologic research is high-
lighted by the number of clinical trials requiring participants: over
12,000 listed by the National Cancer Institute alone (National Can-
cer Institute and National Institutes of Health,2013). Some studies,
though, have shown that only somewhere between 2 and 9% of all
cancer patients actually enroll (Ross et al., 1999; Lara et al., 2001).
For biopsy-driven studies without anticipated clinical benefit, we
can expect the participation rate to decrease, although no formal
evaluation has thus far been reported. The low participation in
clinical trials delays the progression of research and the pursuit of
personalized medicine.
One responsible party for at least broaching the subject of the
patient’s participation in research is the patient’s treating physi-
cian. That physician is best placed to evaluate the patient’s physical
condition, the social and mental status that might preclude the
patient from participating in a trial, and the available avenues for
both treatment and research. However, asking physicians to recruit
their patients into research is not always a simple proposition.
There are practical difficulties that inhibit patient recruitment such
as time constraints, increased workload, and physician specialty
and location (Lara et al., 2001; Klabunde et al., 2011; Kleider-
man et al., 2012). Ethical obligations to promote the health and
well-being of patients – and the treatment of disease as the high-
est priority – might also impact physicians’ decisions to bring
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up research with patients (Galvin et al., 2009; Kleiderman et al.,
2012), as well as conflicts between these obligations and the duty
to undertake research (Emanuel et al., 2008).
However, patient participation in research – a necessity for clin-
ical advancements in personalized medicine – should be at least
a consideration for physicians whose patients fit the criteria of a
particular study. The evidence of patient willingness to partici-
pate (Agulnik et al., 2006) should allay some physician concerns,
and the ethical ideal of autonomy (Beauchamp and Childress,
2009) should encourage at least informing patients of the research
options available.
Yet, even given a willing physician and patient there are still
complexities to the ethical recruitment of patients into research,
especially when non-therapeutic procedures are involved. The goal
of this paper is to examine two of these ethical complexities: volun-
tariness, a bedrock component of informed consent; and conflicts
of interest, a long-term and consistent problem in biomedical
research.
COMPROMISING THE VOLUNTARINESS OF CONSENT
The Nuremberg Code clearly states that research participation be
undertaken “without the intervention of any element of force,
fraud, deceit, duress, over-reaching, or other ulterior form of con-
straint or coercion. . .” (International Military Tribunal, 1949).
This requirement of voluntariness has been confirmed universally
over the years as an essential element of research participation
(World Medical Association, 1964; Canadian Institutes of Health
Research et al., 2010). However, a number of factors have the
potential to compromise the voluntariness of consent by creat-
ing for the patient a risk-benefit perception that does not coincide
with reality. These include the patient-physician relationship itself
and a misunderstanding of the purposes of research (therapeutic
misconception).
In an obvious challenge to voluntariness, a physician explicitly
linking medical care to participation in research (e.g.,“I won’t treat
you unless you participate”) would oblige the patient to comply
with the request of the physician. There are also subtler influ-
ences on the voluntary decision-making of patients. For example,
the mere existence of the patient-physician relationship may cause
patients to participate in a trial (Eggly et al., 2008). Indeed, patients
are more likely to follow the suggestion of their physician because
of the intimate relationship between the two and the dependency
of the patient (Kass et al., 1996; Kleiderman et al., 2012). The say-
ing “doctor knows best” has roots in reality, after all. If a patient
is more likely to take a course of action because the physician is
suggesting it (Ross et al., 1999), the voluntariness of that action
will be questioned.
Therapeutic misconception can also affect patient perception
of research risk and impact the decision to participate. This con-
cept refers to “the notion that unless otherwise informed, research
subjects will assume (especially, but not exclusively, in therapeu-
tic research) that decisions about their care are being made solely
with their benefit in mind” (Appelbaum et al., 1982). The presence
of therapeutic misconception is common in research participants
(Appelbaum et al., 2012; Pentz et al., 2012), and may be partic-
ularly problematic when participants are recruited by their own
physician (de Melo-Martin and Ho, 2008; Kleiderman et al., 2012).
Several factors can influence a patient’s response and compre-
hension, such as trust, (mis)understanding of the science, and
knowing the difference between care and research (Kass et al.,
1996; Lidz and Appelbaum, 2002). Importantly,
“[m]ost people have been socialized to believe that physi-
cians (at least ethical ones) always provide personal care. It
may therefore be very difficult, perhaps nearly impossible, to
persuade subjects that this encounter is different, particularly
if the researcher is also the treating physician, who has pre-
viously satisfied the subject’s expectations of personal care”
(Appelbaum et al., 1987).
Thus, patients might assume that their physician would not sug-
gest enrollment in research if it were not the best care. This is
particularly true when all standard care has been administered
and there remain limited treatment possibilities for the patient,
or when the clinical research is presented as a treatment option
(Miller and Rosenstein, 2003). However, even when a physician
clearly emphasizes that the goal of research is not to provide care,
as is frequently the case for biopsy-driven studies to explore ther-
apeutic resistance, patients sometimes continue to believe that the
research will provide them with direct benefits (Appelbaum et al.,
1987).
Questions of voluntariness implicit in the patient-physician
relationship and through therapeutic misconception do not
assume that all patient decisions to participate in research
are coerced, misinformed, or imposed: in research using adult
patients, capacity, and a reliance on autonomy are generally pre-
sumed. To minimize factors that might compromise voluntari-
ness of consent, candid physician conversations with patients
are very important. The physician has a responsibility to distin-
guish between treatment and research and to clearly explain the
implications for the patient.
CONFLICTS OF INTEREST
Incentives and rewards, both financial and non-monetary, have the
potential to influence the recruitment of patients into research by
both physicians and physician-investigators (Canadian Institutes
of Health Research et al., 2010). These conflicts of interest are
defined as “[t]he incompatibility of two or more duties, respon-
sibilities, or interests . . . as they relate to the ethical conduct of
research, such that one cannot be fulfilled without compromising
another” (Canadian Institutes of Health Research et al., 2010). For
example, physicians may receive funding to participate in research
or to cover travel expenses. Additionally, non-monetary academic
incentives can factor into conflicts of interest. Indeed, the avoid-
ance of anything that could be considered a “conflict” is practically
impossible: the pursuit of knowledge alone, as a clearly stated goal
of biopsy-driven research, is in opposition to the personal inter-
ests of individual research participants. Therefore, the question
becomes one of effect mitigation rather than prevention.
Certainly, some conflicts can and should be avoided, espe-
cially those pertaining to financial incentives (Bekelman et al.,
2003; Wilson, 2010). A financial relationship between the research
institution, study sponsor, and researcher is necessary to cover
the direct costs associated with the research, but funds that
directly benefit the researcher or physician (and to a lesser extent,
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academic institution) are most problematic. Thus, large payments
to researchers, finder’s fees for physicians, and financial stakes in
the company funding a researcher’s study raise obvious concerns
of financial conflicts and are generally prohibited ethically and/or
legally. At the very least, they must be disclosed to research insti-
tutions, ethics review boards, publishers, and, in many instances,
to potential research participants (McCrary et al., 2000; Canadian
Institutes of Health Research et al., 2010).
Conversely, other forms of conflict are more difficult to avoid
in any academic research endeavor. Career advancement, profes-
sional accolades, and sustained research funding are incentives
for physicians to undertake clinical research (Saver, 2012). As
admitted by a researcher overseeing a gene therapy trial:
“To suggest that I acted or was influenced by money is really
offensive to me. . .. I don’t think about how my doing this
work is going to make me rich. It’s about leadership and
notoriety and accomplishment. Publishing in first-rate jour-
nals. That’s what turns us on. You’ve got to be on the cutting
edge and take risks if you’re going to stay on top” (Nelson and
Weiss, 1999).
Thus, academic interests must be balanced with the benefits of
research for the larger population of patients, and physicians
have an obligation to remain objective regarding the care of their
patients in light of the tensions between clinical treatment and
medical research (Miller and Rosenstein, 2003). These more inher-
ent and largely unavoidable conflicts in research are addressed
through disclosure, ethics review, and other protections given to
patients, especially in the initial contact for research recruitment.
SOME SOLUTIONS
Changes in research ethics over previous decades to address vol-
untariness of consent and conflicts of interest foresaw the very
real dangers of physicians recruiting their own patients into
research, even research in which they are not investigators but
are merely serving a peripheral role. However, even when the
research involves higher than minimal risk and no accompany-
ing benefit for participants, this does not mean that patients are
unapproachable.
The performance of non-therapeutic research, like other
human-subject research, requires the consideration of all stake-
holders. Patients, clinicians, researchers, and research nurses and
coordinators all have different perspectives that should be exam-
ined prior to including patients in the research. In a recent pilot
study by Kleiderman et al. clinicians, research nurses and coordina-
tors, and researchers were asked about the barriers they perceived
in recruiting patients into non-therapeutic research as well as any
facilitators that aided in this recruitment. The paper concluded
that ethical risks are important considerations when recruiting
patients but that there are “mechanisms to ensure that they are
appropriately informed of the risks. . .” (Kleiderman et al., 2012).
The solutions we suggest below are geared to promote an informed
consent that minimizes the ethical risks discussed above.
Physicians are possibly in the best position to inform patients of
the existence of studies that might interest or benefit them due to
their inherent knowledge of patients’ health conditions. However,
commentators have pointed out that physicians – especially when
not intimately involved with the research – often do not fully
understand the studies they are proposing to patients, especially
the potential harms and benefits (Daugherty et al., 1995). Physi-
cians should therefore limit their role to that of information
gateway to other health professionals involved in the research,
such as research nurses, research coordinators, or other physicians
(Kleiderman et al., 2012). This could partly absolve physicians
of many of the ethical hurdles they otherwise face. An exam-
ination of these restrictions in the context of the two themes
discussed above – voluntariness and conflicts of interest – demon-
strates the advantages of a limited recruitment role for treating
physicians.
Voluntary consent will always be an issue in any kind of research
recruitment. However, if a person other than the treating physi-
cian explains the non-therapeutic nature of the research in detail
and obtains patient consent, it will reduce the potential for undue
influence of the physician on patient participation. Likewise, con-
flict of interest can be limited by avoiding situations when it is
otherwise possible. Using other members of the research team to
actively recruit and inform patients, and to sign or co-sign consent
forms, will reduce both real and perceived conflicts pertaining to
recruitment.
The use of professionals other than the researcher or patient’s
physician – a neutral third-party – to initiate and maintain con-
tact with the patient/potential participant is not a novel idea. The
investigator in the case of Jesse Gelsinger, who died during a gene
therapy trial, recognized that
The scientists behind the technology believe in the poten-
tial of the technology and pursue its development with
zeal. . .. The crux of the problem is to assure that the sub-
ject receives a balanced and unbiased view of the risks and
benefits of his/her participation in the trial and that s/he can
make decisions without influence or concern over negative
consequences (Wilson, 2009).
Many researchers, as well as the investigating authorities exam-
ining Gelsinger’s death, acknowledge the benefits of a third-
party providing potential participants with unbiased informa-
tion (Wilson, 2010). In addition, the use of patient advocates
to assist in study and consent design has been suggested as
another means to improve transparency and public trust in
research (Katz et al., 2012). These individuals may have a more
patient-centered perspective than members of the research team.
Unfortunately, although the use of someone outside of the
patient-physician relationship to aid in patient recruitment is sug-
gested as an ethically appropriate solution, there has been little
data demonstrating the effectiveness of this in limiting ethical
risks.
We must also point out that the use of a neutral third-party in
the patient recruitment process may imply a limitation on patient
contact with their physician. We do not believe that this is a nec-
essary correlation, and a rigid wall between a patient and treating
physician is not required. Certainly, physicians’ involvement in
recruiting their own patients into research raises ethical concerns,
but the patient-physician relationship need not end. Indeed, the
patient may feel more comfortable knowing that his or her physi-
cian is involved in the research. The use of a third-party to gain
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consent for participation is intended to reduce potential harms
to the patient’s autonomy represented by the physician’s involve-
ment in the research, not infringe upon the patient-physician
relationship.
CONCLUSION
The need for patient participation in research to find personal-
ized solutions to medical conditions and to understand mech-
anisms of resistance will only increase as scientific knowledge
and technology advance. In the drive to find these participants,
physicians will be relied upon because of their familiarity with
their patients’ conditions, as well as information that would
advise against patient involvement, including both physical and
emotional considerations.
The above discussion demonstrates that physicians do not have
to remove themselves from the recruitment process. Although vol-
untariness of consent and conflicts of interest must be monitored
in any research enterprise, these ethical considerations should
not result in a blanket prohibition on physicians recruiting or
talking about research involvement with their patients. Limited
involvement, such as mentioning the existence of a study and
then referring the patient to a member of the clinical research
team or a patient advocate, is one way to mitigate any ethical
concerns. In fact, it is not realistic to prohibit physicians from
discussing potential clinical trial participation to their patients,
especially if we want research to advance on the very conditions
affecting patients and considering that patients may count on their
physician to be aware of ongoing research, whether therapeutic on
non-therapeutic.
It should be noted that these ethical constraints on participant
recruitment are important in any form of medical research, not
just within the context of the studies we focus on in this article.
Although recruiting patients into non-therapeutic research with
more than minimal risk may raise the ethical stakes, similar con-
siderations of voluntariness and conflicts of interest are underlying
currents across all human-subject research.
In order to address these ethical considerations for patient
recruitment into clinical trials, there is a need for better intra-
professional communication about available trials, eligibility cri-
teria, and other relevant information, as well as further research
regarding physicians’ needs when communicating with patients.
In the meantime, by limiting the involvement of treating physi-
cians in the recruitment process we can minimize ethical risks
to achieve greater transparency and professional integrity, so that
research benefits can be maximized for the good of patients and
society.
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